Skip to content

Trial · Interventional

CompletedPhase 4Registry data

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

NCTNCT00079924 (opens ClinicalTrials.gov in a new tab)Other id8141Other idB3D-MC-GHCM
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 4
Enrollment
200 participants
Sponsor
Eli Lilly and Company · Industry
Design
Randomized · Open label (no masking)
Countries
1 country

United States

Start
Nov 2004
Primary completion
Not stated
Completion
May 2007
First posted
19 Mar 2004 (estimated)
Last update posted
25 May 2007 (estimated)
Conditions
Postmenopausal Osteoporosis

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20042005200620072008
  1. Ph 4

    Effects of Teriparatide in Postmenopausal Women With Osteoporosis

    NCT00079924

    Nov 2004 to May 2007

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Effects of Teriparatide in Postmenopausal Women Previously Treated with Alendronate or Raloxifene.

Interventions

  • teriparatideDrug
  • aldrenodateDrug
  • raloxifeneDrug

Arms0

The registry lists no arms for this trial.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Change in calcium values after beginning teriparatide

Secondary outcomes(1)

  1. Frequency of hypercalcemia, various calcium assessments, change in bone mineral density and tests of bone formation and resorption

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2009

14 results

Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

Cosman et al. 2009The Journal of clinical endocrinology and metabolismcited by 127

PMID 19584192DOI 10.1210/jc.2008-2719PUB-19584192

Rights unknown14 results
Source linkSee results (14)

Eligibility

Who could join, as posted.

Sex
Female
Age
from 50 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Postmenopausal women aged at least 50 years * A previous clinical diagnosis of osteoporosis * At high risk for fracture * Current therapy for at least 18 months prior to study entry with either raloxifene HCl or alendronate Na Exclusion Criteria: * History of metabolic bone disease other than osteoporosis * History of malignant neoplasm within the last 5 years except for superficial basal cell carcinoma or squamous cell carcinoma

PepBank is a research reference. Talk to a doctor before you use any peptide.